Alcohol and Substance Abuse Disorders
Released: December 14, 2016
Pharmacotherapies for Alcohol and Substance Abuse (PASA) Consortium Releases New Clinical Funding Opportunity
The Pharmacotherapies for Alcohol and Substance Abuse (PASA) Consortium is funded by the Congressionally Directed Medical Research Programs (CDMRP) as part of its Alcohol and Substance Abuse Research Program (ASARP). The goal of the PASA Consortium is to fund study applications for developing new medications that can be brought to therapeutic use to improve treatment outcomes for alcohol and substance use disorders (ASUD), especially as related to post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI).
This current Clinical Trial Research Funding Opportunity is focused on developing new medications that 1) already have an IND for human studies and 2) that can improve treatment outcomes for ASUD related to PTSD and TBI. The PASA Consortium is administered by a Management Core led by RTI International in collaboration with the Baylor College of Medicine and the Uniformed Services University.
For more information on this opportunity, including application process and timelines, please use the link below:
Last updated Wednesday, December 14, 2016